Popular on eTradeWire
- Mona Clayton, RN Launches Mix & Mentor emPOWER Hour Global Tour at Hotel 50 Bowery 120
- Even Neutral Switzerland Can't Stomach Philip Morris
- Radio Vet Connie Birth returns to The Spin Awards as the Red Carpet host
- Justices Free Up Funding For Trump's Wall
- Variety – The Children's Charity of Wisconsin CEO on Modern Living with kathy ireland®
- Home2 Suites by Hilton Abilene Celebrates Topping Off
- Goldberg Brothers ships new folding barn door hardware
- Armsons teams up with Repton School for new sports facilities
- PC Madness at GWU - Ban Stick Figure Crosswalk "White Man"
- Macy's Caves Over "Fat Shaming," But Maybe It Works
Similar on eTradeWire
- AmbioPharm announces new Sr. VP of Quality
- Saranas Recognized as One of Houston's Most Innovative Companies
- Hydroxy Acid Oxidase Activity Assay Kit
- Braeden Lichti: Deciding when to invest in a biotechnology company
- Caspase-3 Activity Assay Kit (Luminometric)
- New Risk Assessment Tool from SiliconExpert and EMA Design Automation Prevents BOM Rejection
- Exclusive iVeena speaker interview released for 3rd Ophthalmic Drugs Conference
- LDC and ISAR Bioscience Team up to Develop Novel Regenerative Therapies
- Braeden Lichti: Five-basic biotech investing due-diligence principles
- Assay.Works and ISAR Bioscience Team up to Develop Novel Regenerative Therapies
ExpressCells plans to use the $800,000 in proceeds from the first close of its Series A financing to build the commercial and operational infrastructure to sell its knock-in cell lines. This includes operating its lab in Philadelphia and establishing its promotional platform.
"The Series A financing is a significant advance for ExpressCells," said Matt Handel, co-founder and CEO of ExpressCells. "This will allow us to market our novel plasmid technology that will give scientists better cell models for drug discovery and other research purposes. Identification of better lead compounds in the discovery process should result in fewer late-stage failures, reducing the cost of drug development."
More on eTradeWire News
- Dale Dye Selected as Writer of the Year by the Military Writers Society of America (MWSA)
- Coral Springs Center for the Arts to Present Georgia-Based '90s Alternative Rock Band \
- CJV Real Estate Has a New Listing in Wheat Ridge, CO 80214
- WeCutFoam Announces Newly Designed Website Launch
- Pet Products Zone: Highly-Desired Pet Products for Your Four-Legged Friends
ExpressCells' unique plasmid technology, in combination with CRISPR/Cas9, allows the company to deliver custom cell lines in which a new gene has been successfully inserted into the cell's DNA in 25% of the time required with current technologies. The speed of the process allows the company to insert up to three genes into the same cell line in as few as 3 months. ExpressCells will initially focus on inserting "reporter" genes that code for bioluminescent and fluorescent proteins, allowing scientists to more efficiently visualize intracellular activity. ExpressCells will sell both custom cell lines—each designed to meet the specific requirements of an individual scientist—as well as catalog cell lines with predefined combinations of reporter knock-ins.
Mr. Handel continued: "We appreciate the support of the Rowan Innovation Venture Fund and Keiretsu Forum Mid-Atlantic in leading the Series A. Their shared vision for ExpressCells was instrumental in securing the funding and will be critical in the ongoing success of the company."
More on eTradeWire News
- TFG Launches new line of co branded secured credit cards
- AESA Expo at Glendale Tech Week 2019
- AESA Conference at Glendale Tech Week 2019: Call for Abstracts!
- MSP GURU and Cyberfish Partner to Serve their Mutual Clients
- Disability Lifestyle Influencer Releases Debut Book Titled "Rolling Through Life With Mommy"
ExpressCells is a private biotechnology company based in Philadelphia, PA. Our propriety genome editing technology, in combination with CRISPR/Cas9, allows the company to create advanced, knock-in cell lines to enhance drug discovery and other biological research, and shorten the time for delivery of knock-in cell lines by 75% relative to current technologies. Our genetic engineering technology was invented at the Temple University School of Pharmacy by Oscar Perez-Leal, MD. ExpressCells holds a global, exclusive license on this technology. For more information, visit www.xpresscells.com.
- A Guide To Used Car Buying In Canada
- YINCAE - New NC 256 Zero Residue Flux
- Class E Camping: The Essential Camping Products You Need for Successful Nights Outdoors
- E&I Cooperative Awards Indoor Air Quality & HVAC Services Contract to Pure Air Control Services
- Regent Revenue Cycle Management Expands Service Infrastructure to Accommodate Next Phase of Growth
- Professional Boxing Event "Battle of the South" Friday, August 23rd at Atlanta Coliseum
- National Opioid Crisis Expert Dr. John Rosa Encourages Education About The Danger of Taking Pills
- ADL Enhances EMR Functionality for PDPM
- Introducing the Fox&Summit® Wi-Fi Pull Cord Sensor for the Connected Home
- Backpack Health and Project Alive Partner to Advance Hunter Syndrome Research
- Brevard County Surges in Growth; Luxury Housing Struggles to Keep Up
- Clutch recognizes L7 Creative as a Top Advertising & Marketing Agency in San Diego
- Generator Emissions Testing to Maintain EPA Standards
- BSC Capital Partners Invests in Largest Chronic Care Management Provider, ChartSpan
- San Antonio Soft Shell Head Gear and Safety Equipment Representative Announces New Website
- Justice Tax, LLC Believes in Giving Back to Our Community
- Justice Tax, LLC Makes Donation to Dreams Come True
- New Spatial Augmented Reality System Enters Toronto Tech Stream
- The Work Truck Show 2020 marks 20th anniversary of North America's largest work truck event
- Comfort Fit Pets releases another new Dog Harness